Compare Marvell Technology Inc (MRVL) vs Relay Therapeutics Inc. Common Stock (RLAY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Marvell Technology Inc vs Relay Therapeutics Inc. Common Stock — how do they compare? Marvell Technology Inc trades at $280.42 (market cap $255.84B), while Relay Therapeutics Inc. Common Stock trades at $17.5 (market cap $3.94B). The key difference: Marvell Technology Inc is far larger — about 64.9× Relay Therapeutics Inc. Common Stock's market cap, and Marvell Technology Inc pays a 0.08% dividend while Relay Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Marvell Technology Inc for 42 Days and Relay Therapeutics Inc. Common Stock for 0 Days on average.
| MRVL | RLAY | |
|---|---|---|
Market Cap | $255.84B | $3.94B |
Volume | 23,652,500 | 3,432,928 |
Sector | Technology | Health |
52-Week High | $316.43 | $20.75 |
52-Week Low | $73.73 | $6.03 |
Typical Hold Time | 42 Days | 0 Days |
Enterprise Value | $257.20B | $3.06B |
Dividend Yield | 0.08% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Marvell Technology (MRVL) trades at $284.68, down 0.81% on the day, amid strong bullish technical signals and robust analyst optimism. The stock has delivered consecutive earnings beats, with Q2 2026 EPS of $0.94 exceeding expectations, and is supported by a consensus price target of $327.86. Revenue growth is accelerating, driven by data center demand and custom AI chip deals, though valuation multiples remain elevated with a P/E of 94.26.
The outlook is positive, fueled by AI infrastructure investments and raised fiscal 2028 revenue guidance to $18 billion. Key risks include high valuation sensitivity, competitive pressures, and execution challenges in scaling custom chip production. Analyst consensus is strongly bullish, with 84% buy ratings, but investors should weigh growth prospects against premium pricing and market volatility.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Marvell Technology Inc
Marvell Technology is a leading fabless chipmaker focused on networking and storage applications. Marvell serves the data center, carrier, enterprise, automotive, and consumer end markets with processors, optical interconnections, application-specific integrated circuits (ASICs), and merchant silicon for Ethernet applications. The firm is an active acquirer, with five large acquisitions since 2017 helping it pivot out of legacy consumer applications to focus on the cloud and 5G markets.
Read more on MRVL →About Relay Therapeutics Inc. Common Stock
Relay Therapeutics develops precision medicines for oncology and genetic diseases. Its drug discovery platform studies how protein motion affects drug targets to guide small-molecule medicine design.
Read more on RLAY →
